GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Gencurix Inc (XKRX:229000) » Definitions » Ending Cash Position

Gencurix (XKRX:229000) Ending Cash Position : ₩444 Mil (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Gencurix Ending Cash Position?

Gencurix's Ending Cash Position for the quarter that ended in Dec. 2024 was ₩444 Mil.

Gencurix's quarterly Ending Cash Position declined from Jun. 2024 (₩771 Mil) to Sep. 2024 (₩310 Mil) but then increased from Sep. 2024 (₩310 Mil) to Dec. 2024 (₩444 Mil).

Gencurix's annual Ending Cash Position declined from Dec. 2022 (₩5,858 Mil) to Dec. 2023 (₩2,930 Mil) and declined from Dec. 2023 (₩2,930 Mil) to Dec. 2024 (₩754 Mil).

Gencurix Ending Cash Position Historical Data

The historical data trend for Gencurix's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gencurix Ending Cash Position Chart

Gencurix Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial 5,627.56 11,963.73 5,858.16 2,929.69 754.20

Gencurix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,929.69 1,090.90 770.65 310.00 444.19

Gencurix Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gencurix's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2929.693+-2175.496
=754

Gencurix's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.0010000000000332+444.193
=444

Gencurix Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gencurix's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gencurix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Gencurix Inc (XKRX:229000) » Definitions » Ending Cash Position
Comparable Companies
XKRX:246250 XKRX:031860 XKRX:149300 XKRX:221800 XKRX:303360 XKRX:236340 XKRX:086460 XKRX:086040 XKRX:109820 XKRX:347740 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA
Traded in Other Exchanges
N/A
Address
9th Floor, Hanhwa Bizmetro I, Guro 3-dong, Guro-gu, Seoul, KOR, 152-733
Website
http://www.gencurix.com
Gencurix Inc develops diagnosis treatment kits. It offers products including GenesWell BCT, a breast cancer test; GenesWell ddEGFR Mutation Test; GenesWell CDx EGFR Mutation Test; and GenesWell ddEGFR mutation Test.

Gencurix Headlines

No Headlines